Drug intelligence / Profile preview

HB0052

Development stage: Phase 2
Lead developer: Shanghai Huaota Biopharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HB0052 is a **CD73-targeted antibody-drug conjugate (ADC)** in clinical development for the treatment of advanced solid tumors. It acts as a **CD73 inhibitor** (also classifiable as a 5'-nucleotidase inhibitor), aiming to reduce tumor immune evasion by blocking the adenosine pathway mediated by CD73. HB0052 is being assessed for safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced solid malignancies, including pancreatic cancer, hepatocellular carcinoma, and gastric/gastroesophageal junction adenocarcinoma[1][6].

Other names: CD73-ADCCD-73-ADCCD 73-ADCShanghai Huaaotai Biological CD73 ADC

Targets

NT5E (Cluster of Differentiation 73)

Beyond the preview

Go deeper on HB0052.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HB0052.

Explore the full profile